After three months of increasing trial disruptions, the number of disrupted trials began to fall between June and July. Most disruption was caused by the...
The US Federal Government’s Biomedical Advanced Research and Development Authority (BARDA) award of $354m to Phlow Corporation for the manufacture of COVID-19 medicines and other...
South Korea-based bio/pharma company Celltrion has recently agreed to acquire a portfolio of 18 prescription pharmaceutical products and over-the-counter medicines across the Asia-Pacific (APAC) region...
India-based Cipla has recently entered into a partnership with Boehringer Ingelheim (BI) India Pvt. Ltd. to co-market three new oral anti-diabetics drugs in India, mainly...
The Hodgkin’s lymphoma (HL) market is expected to grow from $1.2bn in 2019 to $2.1bn in 2029 across the eight major markets (8MM*) at a...
Following Biogen’s submission of a Biologics License Application (BLA) to the FDA of aducanumab; Alessio Brunello, Managing Pharma Analyst at GlobalData, a leading data and analytics...
Following the news that US biotech Novavax announced it will receive $1.6bn funding for the development of its COVID-19 vaccine candidate NVX-CoV2373; Philipp Rosenbaum, PhD, Senior...
The number of diagnosed prevalent cases of AL amyloidosis is expected to increase from 75,033 in 2019 to 89,637 in 2029 at an annual growth...
The burden of diagnosed Hodgkin lymphoma (HL) is expected to increase at an annual growth rate (AGR) of 0.90% from around 25,000 cases in 2019...
Following the news that Indian pharmaceutical giant Dr. Reddy’s Laboratories (Dr Reddy’s) has signed tripartite agreement with Tokyo-based FUJIFILM Toyama Chemical and Dubai-based Global Response...
Long-term complications arising in COVID-19 patients after recovering from the initial illness are expected to increase healthcare costs in the long-term. Complications such as stroke,...
In the seven major pharmaceutical markets (7MM*), less than half of non-alcoholic steatohepatitis (NASH) cases were diagnosed in 2019, says GlobalData, a leading data and...
Following Bristol Myers Squibb’s positive topline results from its pivotal Phase III TRUE NORTH trial, it is possible that oral sphingosine1‐phosphate (S1P) Zeposia could have...
As the world continues to brace for a COVID-19 triggered economic downturn and with the Brexit transition period extension deadline ending on 30 June; Urte Jakimaviciute,...
Following the US FDA’s issuance of its guidance document; Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, offers his view: “The US Food and...
The COVID-19 pandemic has led to temporarily increased drug sales for biggest bio/pharma companies in the first quarter (Q1) of 2020. This increase over sales...
COVID-19 could be causing patients with Hodgkin lymphoma and other cancers to delay seeking care, which in turn could delay those patients from receiving a...
Since COVID-19 was declared a pandemic in March 2020, social media posts related to the virus from neurology influencers increased significantly, with content peaking in...
Since COVID-19 was declared a pandemic in March 2020, social media posts related to the virus from immunology influencers increased significantly, with content peaking in...
The number of social media posts made by digital pharma influencers related to COVID-19 has increased significantly since it was declared a pandemic in March,...
In the UK and US, there is a pattern of minority ethnic groups having a higher risk of death due to COVID-19 compared with their...
The usefulness of adenovirus-vectored vaccines for COVID-19 is currently questionable as these should only be administered two times over the lifetime of an individual and...
A total *76% of people, as surveyed by GlobalData, expect telemedicine to be used widely once the pandemic had abated. Kathryn Whitney, MSc, Director of Thematic...
At the beginning of June, more than 70% of trials were being run by non-industry sponsors, and the majority of clinical trial sponsors were based...
There are concerns over the pricing of remdesivir and how to make it available in low-income and lower-middle income countries, says GlobalData, a leading data...
Novo Nordisk’s recent announcement of positive topline data from its Phase IIIa study STEP 4, investigating the use of semaglutide to treat obesity, will enable...
The myelodysplastic syndromes (MDS) market is expected to grow from $1.6bn in 2018 to $2.4bn in 2028 across the seven major markets (7MM*) at a...
Following the FDA approval of Ferring Pharmaceuticals’ once-weekly progesterone vaginal ring for luteal phase support in women undergoing assisted reproductive technology (ART) treatment cycles, the...
The health and fitness wearables that monitor physiological parameters such as heart rate, body temperature, sleeping patterns, blood pressure and oxygen saturation levels may become...
Tonix Pharmaceuticals and Southern Research have partnered to create a COVID-19 vaccine based on Tonix’s proprietary horsepox vaccine platform. The use of the horsepox vector...
While researchers investigate recovered patient antibody treatments for COVID-19, intravenous immunoglobulin (IVIg) is a similar type of treatment that is already available and could be...
After receiving a world-first approval by the UK Government, following groundbreaking data showing it can reduce COVID-19 deaths among hospitalized patients, the inexpensive and widely...
Following Gilead’s announcement that it will begin Phase I clinical trials for inhaled remdesivir in healthy volunteers, data and analytics company GlobalData anticipates that a...
Acute myeloid leukemia (AML), a serious haematological cancer, remains a disease often defined by poor prognosis. However, less than 30% of diagnosed incident cases of...
Despite the COVID-19 challenges, most of the big bio/pharma companies had reported temporary increase in drug sales in Q1 2020, mainly due to the stockpiling...
Drug sales for Alzheimer’s disease (AD) and mild cognitive impairment (MCI) collectively reached $2.2bn in 2018 across the eight major markets (8MM*). By the end...
Following the news that Indian drug firms cheer dexamethasone’s efficacy in severe COVID-19 patients;Nag Madhavi, Pharma Analyst at GlobalData, a leading data and analytics company,...
Following the news that domestic pharma giants Cipla and Hetero have received the Drugs Controller General of India’s (DGCI) approval to launch generic versions of...
The launch of new therapies between 2018 and 2028, including new classes of drugs with novel mechanisms of action (MOAs), and an anticipated increase in...
The phase distribution of clinical trials in Europe suggests that sponsors are focusing primarily on repurposing available therapies to treat COVID-19 and that the level...
Following the news that Glenmark Pharmaceuticals has become the first company in India to receive regulatory approval for oral antiviral favipiravir for the treatment of...
BeiGene has recently received approval for its second-generation Bruton's tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib) from the China National Medical Products Administration (NMPA). The China-based...
COVID-19 deaths are most likely being underreported in the US, according to GlobalData, a leading data and analytics company. Excess deaths measure the difference between observed...
The burden of diagnosed myelodysplastic syndrome (MDS) is expected to increase at an annual growth rate (AGR) of 2.40% from around 90,000 cases in 2018...
Comorbidity is a major concern in people with angina pectoris as, in 2019, there were nearly 20 million diagnosed prevalent cases of angina pectoris in...
Countries are beginning to reopen due to economic and social pressures, while keeping an eye on the threat of resurgences. Based on trends observed in...
In order to achieve ‘herd immunity’ to COVID-19, there are estimates that anywhere from 50–90% of the population will need to achieve immunity. This will...
The COVID-19 pandemic presents significant growth opportunities for mental health and wellbeing technologies, however, telemedicine cannot replace in-person visits and these innovations will not resolve...
The acute myeloid leukemia (AML) market is expected to grow from $1.4bn in 2019 to $5.1bn in 2029 across the eight major markets (8MM*) at...
The International Alliance of Amyotrophic Lateral Sclerosis (ALS)/ Motor Neuron Disease (MND) Associations, recognizes June 21 as the ALS Global Day. The goal of this...
Following the recent news that Royal Philips has launched its Avalon CL Fetal and Maternal Pod and Patch obstetrics monitoring solution for high-risk expectant mothers; Dominic...
Despite receiving Food and Drug Administration (FDA) approval for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) before Novartis’s Cosentyx (secukinumab), Eli Lilly’s Taltz (ixekizumab) will...
Serum Institute of India (SII) is the world’s largest vaccine producer in terms of volume. SII is currently working on three candidates for COVID-19, including...
The pharma sector saw promising year-on-year (YoY) growth in 2019, compared to the previous year, with 16 of the top 20 companies by market capitalization...
Oral selexipag could improve treatment for the pediatric population based on its convenient administration, better safety and better tolerability profile compared to currently available options...
The clean energy sector had been one of the biggest and fastest-growing sectors in the US since 2015, having employed over 3 million people. However,...
As the COVID-19 pandemic continues to evolve across the globe, a large amount of data on its epidemiology has been generated. Finding relationships and predictive...
Latin American countries are showing dangerous trends of increasing COVID-19 cases. Brazil, Peru, Chile, and Mexico are now ranked second, tenth, thirteenth, and fourteenth, respectively,...
More than 200 trials that were previously disrupted from the COVID-19 pandemic by delayed initiation and slow or suspended enrollment are now ongoing or completed....
The global COVID-19 pandemic has become a catalyst for the pharma industry and the US Food and Drug Administration (FDA) to implement long-awaited innovations. The...
Following the publication of a new study of the long-term effectiveness of midomafetamine (MDMA) for the treatment of post-traumatic stress disorder (PTSD);Philippa Salter, Neurology Analyst...
Following today’s news (Monday 15 June) that the FDA has pulled emergency use authorization of hydroxychloroquine for COVID-19;Johanna Swanson, Product Manager at GlobalData, a leading...
Gilead is likely preparing for remdesivir’s approval and launch, based on an analysis of GlobalData’s Job Analytics database. As an operational reaction to the COVID-19...
Moderna’s mRNA-1273 vaccine for COVID-19 is currently in Phase I development and is targeted for an aggressive commercial launch in 2021. The vaccine candidate’s peak...
Following the news that the Indian state of Maharashtra is planning to procure Gilead Sciences' antiviral drug remdesivir from Bangladesh-based pharmaceutical giant Eskayef Pharmaceuticals; Anupama...
Moderna Therapeutics recently received Fast-Track designation from the FDA for its COVID-19 candidate vaccine, mRNA-1273 together with the green light to initiate a Phase II clinical...
After a little over 100 days since the first confirmed case of COVID-19 reported on 28 February 2020, New Zealand has lifted almost all restrictions...
COVID-19 presents a challenge to physicians managing patients with multiple sclerosis (MS), due to concerns about using immunotherapies to treat this neurological condition, in the...
A recent research study showed that for 16 COVID19 positive women there were evidences that their placentas had blood clots and indications of abnormal blood...
While Gilead Sciences’ remdesivir has been declared the new standard of care for COVID-19 despite some mixed trial results, it will continue to face challenges...
GlobalData anticipates that Gilead’s remdesivir will target a select severity group of COVID-19 patients, and it remains questionable as to how treatment with the drug...
Based on the current trajectory of COVID19 daily confirmed cases, India will be the fourth most heavily affected country in the world behind the US,...
Remicade (infliximab) and Humira (adalimumab) are the established anti-tumor necrosis factor (TNF) therapies that have been shown to decrease inflammation in diseases such as rheumatoid arthritis (RA) and...
Even though blockchain stands out as a potential solution to improve pharmaceutical supply chains, COVID-19 may become a hindrance rather than a trigger in the...
The ongoing COVID-19 pandemic has increased the demand for drugs used to sedate the mechanically ventilated COVID-19 patients and has resulted in shortages for some of these...
The local production of the active pharmaceutical ingredients (API) for some of the key COVID-19 repurposed drugs including remdesivir, favipiravir and hydroxychloroquine (HCQ) is likely to offer a...
Ferring Pharmaceuticals recently gained FDA approval for Milprosa, a once-weekly progesterone vaginal ring for the luteal phase support in women undergoing Assisted Reproductive Technology (ART)...
The launch of the generic versions of dasatinib, following the expiration of Indian patent in April 2020 will increase the accessibility for treatment of chronic...
Following the news that India-based Sun Pharmaceutical Industries Ltd (Sun Pharma) has received Indian regulatory approval to start clinical trials of pancreatitis drug nafamostat mesylate in COVID-19 patients; Prashant...
At least 49 publicly traded bio/pharmaceutical companies took Paycheck Protection Program (PPP) loans from the US Government’s $659bn program despite official guidance that the money...
The Drug Controller General of India (DCGI) has recently given approval to Indian pharma companies Glenmark and Strides Pharma Science to initiate clinical trials of...
The US remains the most heavily affected country by the COVID-19 pandemic, with more than 1.7 million total confirmed cases. In comparison, South Korea is now thought...
In Japan, the plaque psoriasis (PsO) treatment landscape is highly competitive with the availability of conventional topical therapies, as well as biologics including anti-TNF, anti-IL-17, anti-IL-23 inhibitors, and...
The concept of an immunity passport is under scrutiny and it is crucial that the underlying scientific, ethical, legal and practical issues must be addressed...
The elderly and those with pre-existing conditions have now been drafted onto the front lines in order to restart economies as we face a balancing...
Novo Nordisk’s recent announcement of positive topline data from its Phase IIIa study STEP 4, investigating the use of semaglutide to treat obesity, will enable...
The clinical trial landscape has had multiple disruptions due to the COVID-19 pandemic, including the cardiovascular and metabolic disorder (CVMD) space. Despite a few trials...
As Gilead Sciences’ remdesivir continues to steal the COVID-19 spotlight, the antiviral is likely to be considered for inclusion in the top-secret US Strategic National...
Following the news that India-based BDR Pharmaceuticals has sought the Drug Controller General of India (DCGI)'s approval to manufacture and sell the generic version of...
The number of deals announced in the global healthcare sector grew by 0.6% during the week ended May 24, 2020 compared to the previous week,...
Although the number of clinical trials that have suspended enrolment due to COVID-19 is leveling off, the overall disruption of trials continues to expand, says...
Pharmaceutical software development has been less impacted by the COVID-19 crisis as it facilitates remote working and already had group collaboration tools and software processes...
A new report, published in Nature Reviews Drug Discovery, reveals that the cellular immunotherapy landscape continues to expand, with 472 more cellular therapies in development now...
Following the FDA’s safety review on sodium glucose-transporter-2 (SGLT-2) inhibitors, a label update was issued stating that patients undergoing any scheduled surgery should discontinue treatment...
The number of deals announced in the global healthcare sector (including pharmaceuticals and medical equipment) declined by 6.8% during the week ended May 17, 2020...
The COVID-19 pandemic caused a decrease in childhood vaccinations as preventative care was disrupted by the pandemic. The lack of vaccination could lead to another...
Alexion is investigating monoclonal antibody treatments Soliris (eculizumab) and Ultomiris (ravulizumab-cwvz) as potential therapeutics for COVID-19. While these drugs have established safety data, they both...
Yale University launched a clinical trial of ibudilast (MN-166) to assess it as a treatment for COVID-19 patients with acute respiratory distress syndrome (ARDS), a...
An estimated 70–80% of ventilated patients will experience ICU delirium, which causes patients to enter a confused state and can lead to long-term cognitive impairments...
The University of Oxford has reported positive findings from preclinical animal studies of its potential COVID-19 vaccine ChAdOx1, which involved nine rhesus macaques. The vaccine...
The diagnosed prevalent cases of angina pectoris is expected to increase from 19.58 million cases in 2018 to 22.79 million cases in 2028, at an...
Italy is a major active pharmaceutical ingredient (API) supplier to the global market, and its stringent lockdown measures has caused disruption of the supply chains that relied...
Researchers from Washington University School of Medicine are now conducting a clinical trial of antidepressant drug fluvoxamine, as a potential treatment for the ‘cytokine storm’...
In response to the global pandemic, biopharma companies have put a renewed emphasis on finding treatments for infectious diseases, including COVID-19 and other infectious diseases...
Clinical trials across the globe continue to be disrupted due to COVID-19. According to GlobalData, a leading data and analytics company, among global clinical trials that have been...
In the nine major pharmaceutical markets (9MM*), less than half of age-related macular degeneration (AMD) cases were diagnosed in 2019 in adults aged 50 years...
With the scale and complexity of cybercrime increasing, and the fact that hospitals are moving toward digitalization and remote patient care, the number of cyberattacks...
Following the news that Indian Council of Medical Research (ICMR) and India-based Bharat Biotech have partnered to develop an indigenous COVID-19 vaccine; Anupama, Pharma Analyst at GlobalData, a...
Japan has already witnessed a significant downturn in the number of new daily COVID-19 cases since the national emergency was declared. However, the country is likely to see...
Despite the COVID-19 outbreak, China managed to launch its national blockchain-based service network (BSN) in April 2020, as scheduled earlier, in an attempt to promote the mass...
The Department of Science and Technology - Science and Engineering Board (DST-SERB) has recently initiated several special research projects. These efforts could help contain community spread of the...
Following the news that India has approved nearly US$2bn* towards ‘India COVID-19 Emergency Response and Health System Preparedness Package’; Sasmitha Sahu, Pharma Analyst at GlobalData, a leading data...
With an unexpected spike in COVID-19 cases, India has extended the countrywide lockdown till 17 May 2020. The move reflects India’s dependency on lockdown to contain the pandemic...
Organizations are relying on real-world evidence (RWE) to help tcontain the spread of COVID-19. Real-world data can provide valuable insights to help organizations better understand,...
With the EMA announcing today that it will start a rolling review of Gilead Sciences’ remdesivir for COVID-19 and wide expectations that US Emergency Use Authorization (EUA)...
Following the news that India-based Strides Pharma has developed and commenced the export of generic favipiravir antiviral tablets to potentially treat COVID-19 infection; Sasmitha Sahu, Pharma Analyst at GlobalData, a...
India-based Wockhardt Ltd has recently received US FDA qualified infectious disease product (QIDP) status for WCK 677 (currently filed Investigational New Drug Application/Clinical Trial Application (IND/CTA)) to...
The rheumatoid arthritis (RA) treatment landscape in Japan is highly competitive with many novel disease-modifying anti-rheumatic drugs (DMARDs). To stay ahead of the competition, the branded support offered...
Roche’s Actemra (tocilizumab) generated $687m in the first quarter of 2020, a 30% increase compared to the same period in 2019, due to evidence of...
India-based Natco Pharma has recently launched a generic version of AstraZeneca’s patented anti-diabetes drug Forxiga (dapagliflozin). Natco’s sodium glucose co-transporter-2 (SGLT2) inhibitor, Dapnat, is indicated for the treatment...
Following the news that China trials of Gilead Sciences Inc’s antiviral drug remdesivir in patients with mild symptoms of coronavirus (Covid-19) have been suspended due...
The Biomedical Advanced Research and Development Authority (BARDA) has agreed to provide up to $483m to assist Moderna in developing its COVID-19 vaccine candidate, but reporting...
The American Society of Reproductive Medicine (ASRM) issued guidance on fertility treatments during COVID-19 and called for suspension of most new treatment cycles such as...
Novartis’ Isturisa (osilodrostat) leads recent innovation in Cushing’s disease (CD) with its latest Food and Drug Administration (FDA) approval, says GlobalData, a leading data and...
A number of pharmaceutical companies have RNA-based therapeutics and vaccines in development for COVID-19. However, there are a number of safety concerns around the use of viral vectors with...
India-based Curadev’s licensing agreement with Bayer in March 2020 for the discovery and development of novel stimulator of interferon genes (STING) antagonists across indications with high unmet...
The pharmaceutical market for age-related macular degeneration (AMD) was worth an estimated $8.6bn across the nine major markets (9MM*) in 2018. This is expected to grow to $18.7bn in 2028 at a modest compound annual growth rate...
India's coronavirus (Covid-19) lockdown has impacted the manufacturing and supply chain operations of pharmaceuticals despite pharmaceutical manufacturing being considered an essential service and excluded from the lockdown. However,...
With the global COVID-19 pandemic, many patient groups are at an increased risk of infection and this extends to rheumatology patients prescribed immunosuppressant medication. The...
There has been an overall increase in clinical trials that have pushed back their estimated start dates since the beginning of January 2020, largely due...
With many countries putting clinical trials studies on hold, pharmaceutical companies are shifting their overall priorities away from some current indications toward COVID-19. This could...
Novartis has taken a lead in actively promoting heart failure awareness across India through unbranded digital initiatives that can successfully deliver message to a large population at risk,...
Biomarkers are a beneficial tool in the search for a COVID-19 vaccine and will help speed up clinical trials, reduce costs of development, guide subject...
Novo Nordisk will continue to dominate a large share of the glucagon-like peptide-1 receptor agonist (GLP-1RA) market with the arrival of Rybelsus and Ozempic’s strong global sales of $1.65bn in 2019. This will enable the company to maintain its well-established position in the wider diabetes market, according to GlobalData, a leading data and analytics company. Akash Patel...
Use of virtual mental health tools is expected to rise significantly over the coming months as self-quarantine and social distancing measures show no signs of being lifted, says GlobalData, a leading data and analytics company. Kathryn Whitney, MSc,...
As the number of confirmed COVID-19 cases reaches nearly 1.5 million worldwide, with almost 430,000 in the US alone, the urgency of finding a treatment mounts. One of...
As the COVID-19 pandemic grows across the world, companies are beginning to accelerate their clinical trials for therapeutics and the number of trials has been...
There has been an increase in clinical trial delays due to concerns for patient and investigator safety, travel restrictions, subject quarantine, clinical site closures and...
The COVID-19 pandemic has disrupted nearly every part of supply chains within the healthcare industry, once again exposing the vulnerabilities of many organizations, especially those...
Gilead Sciences’ remdesivir is more likely to work in mild-to-moderate COVID-19 patients rather than severe cases, according to reporting from Reynald Castañeda, Pharma Writer for the Investigative...
Given the speed and rapidity of spread of the COVID-19 epidemic, identifying already available compounds to use on patients has the promise of being able...
With the advent of COVID-19 reaching over one million cases worldwide, a concerted effort will be needed to approach this growing problem. Drug development partnerships...
As COVID-19 spreads, the search for a treatment is ramping up. The antimalarial and immunosuppressant hydroxychloroquine has received some attention, including that of President Trump. There are currently around 60 planned...
In this unprecedented time of uncertainty, key markets have lost 20–70% of their value year-to-date due to COVID-19, according to GlobalData’s COVID-19 Executive Briefing. Sharon Cartic,...
As the COVID-19 situation grows, intensive care units (ICUs) in hospitals have to handle more patients with severe cases of the virus. COVID-19 can be...
It is likely that Italy has reached a peak in COVID-19 transmissions as the country has seen a continued decrease in new laboratory-confirmed cases for...
Following the introduction of social distancing measures, brought in to reduce the spread of COVID-19 across the globe;Emily Carter-Richardson, Pharma Analyst at GlobalData, a leading...
In the race to find treatments for COVID-19, repurposing therapies already approved for other indications to fight the SARS-CoV-2 virus is one key strategy. Approved...
Alexion Pharmaceuticals is revving up to enter the COVID-19 drug development race with Soliris (eculizumab), a drug that is already approved for other indications, a source...
An estimated 1.5 billion people around the world have been asked to practice social distancing amid the outbreak of coronavirus (COVID-19) that has caused the...
While checkpoint inhibitors as monotherapies have fulfilled expectations in some indications, novel combinations are on the horizon in a broader range of cancers says GlobalData,...
In the key markets most heavily affected by the coronavirus (COVID-19), case trends are expected to follow a low-risk forecast, with the exception of the...
COVID-19 has a significant impact on patients with pre-existing conditions, many of which fall under the cardiovascular (CV) and metabolic disorder (CVMD) category. The current...
Thepneumococcal vaccines market is expected to grow from $5.11bnin 2018 to $6.24bnin 2028across the nine major markets (9MM*) at a compound annual growth rate (CAGR)...
Thus far, the novel coronavirus (COVID-19) pandemic has surpassed 860,000 confirmed cases globally and while the economic impact is weighing heavily across sectors, organizations are exploring creative ways of how to combat the outbreak. The responses are not only fighting COVID-19, supporting the general public and propping up the healthcare system,...
Of the more than 230 nanopharmaceuticals in clinical development, 75% are for oncology indications, including many hard-to-treat cancers with few treatment options, according to GlobalData, a leading data and analytics company. Nanopharmaceuticals have many physical and biological advantages...
Following a number of recent global news stories about viral load and its impact on Coronavirus (COVID -19) patients; Michael Breen, Director of Infectious Diseases at GlobalData,...
As the novel coronavirus (COVID-19) pandemic continues to spread globally, virtual platforms will experience an extra boost after already having a transformational impact on the...
The FDA recently lifted an import ban it had imposed in 2015 on India’s Ipca Laboratories due to quality issues and non-adherence to good manufacturing...
The value of the US transcatheter mitral valve repair (TMVR) device market was just over $250m in 2019 and is set to be worth $1.4bn by 2028...
Novartis recently announced new anticipated long-term positive data for its one-time infusion gene therapy, Zolgensma (onasemnogene abeparvovec-xioi), which is set to help the drug generate global...
Following the recent news that the coronavirus (COVID-19) has now spread across 176 countries with approximately 530,000 total confirmed cases worldwide as of 27.03.20; Katie Wrenn, Associate...
As the number of global coronavirus (COVID-19) cases continues to rise, governments around the world are taking unprecedented measures, to contain the spread and support their economies...
With several mega cap biopharma companies having their vital manufacturing steps in Chinese facilities, the novel coronavirus (Covid-19) outbreak is putting the complicated global biopharma industry's supply chain...
Following the news that India has approved US$1.3bn* (INR10Kbn) healthcare package to boost the domestic manufacturing of active pharmaceutical ingredients (API); Prashant Khadayate, Pharma Analyst at GlobalData, a leading data and...
The current multiple sclerosis (MS) pipeline is strong and diverse with a total of 49 products in all stages and phases of clinical development. However,...
Synairgen has received approvals from the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA) to conduct a trial of SNG001 (inhaled...
Use of telemedicine in the US has been low to date. However, it is expected that demand for these services will increase dramatically over the...
The axial spondyloarthritis (axSpA) market across the five growth markets (5GM*) in the Asia-Pacific (APAC) region will experience moderate growth over the next 10 years,...
There has been an exponential increase of coronavirus (COVID-19) cases in the US since the beginning of March, from less than 70 to more...
The impact of the coronavirus (Covid-19) outbreak on industries ranging from technology to automotive has been the subject of intense analysis in the recent months. This has...
Diagnosed incident cases of renal cell carcinoma (RCC) in the eight major markets (*8MM) are projected to increase from 0.20 million cases in 2018 to...
The numbers of breast cancer cases in men are growing steadily in the US. Epidemiologists at leading data and analytics company GlobalData forecast an increase...
Out of all the drugs that are currently in the pre-registration phase and are expected to launch in 2020, ten have the potential to reach...
The systemic lupus erythematosus (SLE) and lupus nephritis (LN) market is expected to grow from $935.9M in 2018 to $1.6bn by 2028 across the seven...
The financial burden of diagnosed bladder cancer is expected to grow between 2018 and 2028 in the seven major markets (7MM)* due to an increase...
The statement from the World Health Organization (WHO) that we are in “uncharted territory” on the coronaries outbreak comes as no surprise as Covid-19 infections...
Gut bacteria research is seeing a resurgence in drug development, including beyond gastrointestinal disorders, with pharmaceutical companies diving into microbiome-focused cancer therapeutic candidates. Experts, however,...
Digital marketing in pharma is gaining increasing importance in recent times and Indian multinational pharmaceutical company Cipla Limited can be termed as a pioneer in this space from...
The financial burden of diagnosed bladder cancer is expected to grow between 2018 and 2028 in the seven major markets (7MM)* due to an increase...
There are currently 445 chimeric antigen receptor (CAR-T cell) therapies under development by companies headquartered across the Asia-Pacific (APAC) region. With research in progress and increased understanding of...
As patients, clinicians and researchers prepare for Rare Disease Day on February 29 2020, GlobalData’s analysis shows the number of drugs awarded orphan drug designations...
Following today’s news that Clover and GSK have announced a research collaboration to evaluate a coronavirus (COVID-19) vaccine, and also that the US government wants...
Following the news that the Food and Drug Administration (FDA) has approved Vyepti for the prevention of migraines in adults, Philippa Salter, Neurology and Ophthalmology Analyst at GlobalData, a leading data and analytics company, offers her view: “Vyepti becomes the latest FDA approved drug for prevention of migraines in adults, following the approval of Amgen’s Aimovig, Eli Lilly’s Emgality and...
Current treatment options for dry eye syndrome (DES) are limited to artificial tears, mostly on its own for milder forms of DES and in combination with anti-inflammatory and corticosteroid therapies for more severe forms of DES. However, this treatment paradigm is expected to see...
A new case definition for COVID-19 in China has resulted in a spike in the number of reported cases of the disease, says GlobalData, a...
Following the recent official gazette notification from the Ministry of Health & Family Welfare (MOHFW) of India that from March 2021 onwards Indian pharmaceutical companies that market drugs...
India-based Zydus Cadila’s licensing agreement with China Medical System (CMS) Holdings Limited in January 2020 for the development and commercialization of desidustat will provide a momentous boost...
Oncology is set to dominate the clinical trials activity in 2020 based on an early preview of trials that are expected to start and be...
Following the failure of a trial for two monoclonal antibody drugs for Alzheimer’s disease (AD), Eli Lilly’s solanezumab and Roche’s gantenerumab, in patients that have...
In 2020, big data and artificial intelligence (AI) will continue to trend as integral parts of the future of pharmaceutical research and healthcare service delivery,...
China-based Qilu Pharmaceutical received approval in December 2019 for QL-1101 under the trade name Ankada, a biosimilar to Avastin (bevacizumab), to treat advanced, metastatic or recurrent non-small-cell...
In recent years, an increasing number of partnerships have been forged between large technology companies, start-ups developing healthcare-specific applications, hospitals, and research centers in the...
As 2020 commences for the pharmaceutical industry, Fern Barkalow, PhD, Senior Director of Oncology and Hematology, as well as members of her analyst team at...
Following the news that Roche reported positive results from Part 2 of the pivotal FIREFISH trial for spinal muscular atrophy (SMA) patients; Vinie Varkey, Senior Analyst...
The human immunodeficiency virus (HIV) pipeline is robust, with 450 products in active development that display a high degree of novelty and diversity. Promisingly, there are 87 first-in-class products that act on a range of 50 molecular targets, which can broadly be...
Nearly three quarters of global industry stakeholders identified immuno-oncology (I-O) or personalized medicine as the most impactful trends that will shape the pharmaceutical sector in...
The heart failure (HF) market is expected to grow from $3.7bn in 2018 to $22.1bn in 2028 across the eight major markets (8MM*) at an...
The pharmaceutical industry is mixed on the factors that will have the greatest positive impact on the industry in 2020, with patent expiry of biologics and vertical integration highlighted as some of the key...
In 2020, drug pricing pressure from regulators and payers will remain and aggressive negotiation tactics to drive down drug prices will continue, according to GlobalData,...
The multiple sclerosis (MS) therapeutics market has entered an exciting phase, with an upsurge of available treatment options and several promising late-stage pipeline products offering...
The global pharmaceutical industry spends a significant amount of revenue on research and development (R&D) activities that are failing to deliver projected returns. A recent...
The number of immuno-oncology (IO) therapies in clinical development and volume of clinical investigations testing these therapies for the treatment of cancer patients continue to grow, and will...
Following the news that Novartis’ Sandoz is handing sole responsibility for the commercialization of the reSET and reSET-O prescription digital therapeutics (DTx) back to Pear...
Following the news that ICER has published its latest draft of the evidence report, ‘Janus Kinase Inhibitors for Rheumatoid Arthritis: Effectiveness and Value’; Rose Joachim, Pharmaceutical...
China is currently the second largest pharmaceutical market in the world. Big data and artificial intelligence (AI) will have significant technological impact across all the...
The luminal unfolding microneedle injector (LUMI) capsule in development at MIT in collaboration with scientists from Novo Nordisk, aims to orally deliver drugs that would...
From 2014 to the first half (H1) of 2019, there were more than 1,300 separate strategic partnerships and 1,000 licensing agreements made in the global...
From 2014 to the first half (H1) of 2019, the pharmaceutical and healthcare industry recorded 2,882 deals that fell within the gene therapy, immuno-oncology, microbiome...
From 2014 to the first half (H1) of 2019, the global pharmaceutical industry saw more than 400 mergers and acquisitions (M&A) in the gene therapy,...
The Indian Pharmaceutical Alliance (IPA) has recently urged the government to set up a fund to boost technological innovation in the bio/pharma space. This push...
Following the recent news that China has revised its drug laws to remove drugs that are legal in foreign countries but not approved in China...
